{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:15:14Z","timestamp":1793650514561,"version":"4.5.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40257-025-00932-0","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T09:22:28Z","timestamp":1744363348000},"page":"611-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"nct03570749","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03899259","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-4616","authenticated-orcid":false,"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Maria","family":"Piraccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Blume-Peytavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Sontag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dutronc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Kolodsick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"1","key":"932_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/ph15010048","volume":"15","author":"M Alexander","year":"2021","unstructured":"Alexander M, Luo Y, Raimondi G, O\u2019Shea JJ, Gadina M. Jakinibs of all trades: inhibiting cytokine signaling in immune-mediated pathologies. Pharmaceuticals (Basel). 2021;15(1):48. https:\/\/doi.org\/10.3390\/ph15010048.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"932_CR2","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","volume":"147","author":"W Damsky","year":"2021","unstructured":"Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147(3):814\u201326. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"932_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/1744666X.2023.2200166","volume":"19","author":"CM Kincaid","year":"2023","unstructured":"Kincaid CM, Arnold JD, Mesinkovska NA. Baricitinib as the first systemic treatment for severe alopecia areata. Expert Rev Clin Immunol. 2023;19(6):565\u201373. https:\/\/doi.org\/10.1080\/1744666X.2023.2200166.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"932_CR4","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Tha\u00e7i D, Torrelo A, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat. 2023;34(1):2161812. https:\/\/doi.org\/10.1080\/09546634.2022.2161812.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"932_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1093\/bjd\/ljac059","volume":"188","author":"B King","year":"2023","unstructured":"King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. Br J Dermatol. 2023;188(2):218\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljac059.","journal-title":"Br J Dermatol"},{"issue":"3","key":"932_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003302","volume":"9","author":"E Morand","year":"2023","unstructured":"Morand E, Smolen JS, Petri M, Tanaka Y, Silk M, Dickson C, et al. Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis. RMD Open. 2023;9(3): e003302. https:\/\/doi.org\/10.1136\/rmdopen-2023-003302.","journal-title":"RMD Open"},{"issue":"6","key":"932_CR7","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266\u201376. https:\/\/doi.org\/10.1111\/bjd.14403.","journal-title":"Br J Dermatol"},{"issue":"3","key":"932_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):335\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"932_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","volume":"189","author":"A Torrelo","year":"2023","unstructured":"Torrelo A, Rewerska B, Galimberti M, Paller A, Yang CY, Prakash A, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023;189(1):23\u201332. https:\/\/doi.org\/10.1093\/bjd\/ljad096.","journal-title":"Br J Dermatol"},{"issue":"10401","key":"932_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","volume":"402","author":"AV Ramanan","year":"2023","unstructured":"Ramanan AV, Quartier P, Okamoto N, Foeldvari I, Spindler A, Fingerhutov\u00e1 \u0160, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(23)00921-2.","journal-title":"Lancet"},{"key":"932_CR11","unstructured":"Compassionate use protocol for the treatment of autoinflammatory syndromes. ClinicalTrials.gov identifier: NCT01724580. Updated October 23, 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01724580. Accessed 18 Jul 2024."},{"key":"932_CR12","unstructured":"A study of baricitinib (LY3009104) in adult and pediatric Japanese participants with NNS\/CANDLE, SAVI, and AGS. ClinicalTrials.gov identifier: NCT04517253. Updated April 22, 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04517253. Accessed 18 Jul 2024."},{"issue":"3","key":"932_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","volume":"24","author":"O Kwon","year":"2023","unstructured":"Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443\u201351. https:\/\/doi.org\/10.1007\/s40257-023-00764-w.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"932_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/jdv.19665","volume":"38","author":"M Senna","year":"2024","unstructured":"Senna M, Mostaghimi A, Ohyama M, Sinclair R, Dutronc Y, Wu WS, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024;38(3):583\u201393. https:\/\/doi.org\/10.1111\/jdv.19665.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"18","key":"932_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, BRAVE-AA Investigators, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2110343.","journal-title":"N Engl J Med"},{"issue":"3","key":"932_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, National Alopecia Areata Foundation, et al. Alopecia areata investigational assessment guidelines: part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2003.09.032.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"932_CR17","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s13555-023-00937-9","volume":"13","author":"P George","year":"2023","unstructured":"George P, Jagun O, Liu Q, Wentworth C, Napatalung L, Wolk R, et al. Incidence rates of infections, malignancies, thromboembolism, and cardiovascular events in an alopecia areata cohort from a US claims database. Dermatol Ther (Heidelb). 2023;13(8):1733\u201346. https:\/\/doi.org\/10.1007\/s13555-023-00937-9.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"932_CR18","unstructured":"Olumiant (baricitinib) [package insert]. Indianapolis (IN): Eli Lilly and Company; 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s007lbl.pdf. Accessed 18 Jul 2024."},{"key":"932_CR19","unstructured":"Xeljanz (tofacitinib) [package insert]. New York (NY): Pfizer; 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. Accessed 18 Jul 2024."},{"key":"932_CR20","unstructured":"Rinvoq (upadacitinib) [package insert]. North Chicago (IL): AbbVie; 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s003lbl.pdf. Accessed 15 Jul 2024."},{"issue":"3","key":"932_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","volume":"41","author":"N Li","year":"2022","unstructured":"Li N, Gou ZP, Du SQ, Zhu XH, Lin H, Liang XF, et al. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41(3):677\u201388. https:\/\/doi.org\/10.1007\/s10067-021-06003-z.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"932_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","volume":"77","author":"PC Taylor","year":"2018","unstructured":"Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018;77(7):988\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212461.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"932_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.25259\/IJDVL_726_19","volume":"87","author":"M Nasimi","year":"2021","unstructured":"Nasimi M, Shakoei S, Abedini R, Ghandi N, Faghihi Z. A cross-sectional study of metabolic syndrome in patients with alopecia areata. Indian J Dermatol Venereol Leprol. 2021;87(3):427\u20139. https:\/\/doi.org\/10.25259\/IJDVL_726_19.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"932_CR24","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","volume":"157","author":"MC Schneeweiss","year":"2021","unstructured":"Schneeweiss MC, Kim SC, Wyss R, Jin Y, Chin K, Merola JF, et al. Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases. JAMA Dermatol. 2021;157(7):805\u201316. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1570.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"932_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMra1202117","volume":"368","author":"JJ O'Shea","year":"2013","unstructured":"O\u2019Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161\u201370. https:\/\/doi.org\/10.1056\/NEJMra1202117.","journal-title":"N Engl J Med"},{"issue":"4","key":"932_CR26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"932_CR27","unstructured":"Litfulo (ritlecitinib) [package insert]. New York (NY): Pfizer; 2023. Available from: https:\/\/www.accessdata.fda.gov\/spl\/data\/4de417fe-fb93-4b56-84bc-20763a43b323\/4de417fe-fb93-4b56-84bc-20763a43b323.xml. Accessed 3 Jul 2024."},{"key":"932_CR28","unstructured":"Cibinqo (abrocitinib) [package insert]. New York (NY): Pfizer; 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf. Accessed 17 Jul 2024."},{"key":"932_CR29","unstructured":"Janus kinase (JAK) inhibitors: drug safety communication: FDA requires warnings about increased risk of serious heart-related events, cancer, blood vlots, and death. 2021. Avalable from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk. Accessed 10 June 2024."},{"issue":"4","key":"932_CR30","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1007\/s12325-023-02445-w","volume":"40","author":"PC Taylor","year":"2023","unstructured":"Taylor PC, Bieber T, Alten R, Witte T, Galloway J, Deberdt W, et al. Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications. Adv Ther. 2023;40(4):1867\u201383. https:\/\/doi.org\/10.1007\/s12325-023-02445-w.","journal-title":"Adv Ther"},{"issue":"11","key":"932_CR31","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","volume":"39","author":"T Bieber","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, Harigai M, Haladyj E, Ball S, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910\u201360. https:\/\/doi.org\/10.1007\/s12325-022-02281-4.","journal-title":"Adv Ther"},{"key":"932_CR32","doi-asserted-by":"publisher","first-page":"11718","DOI":"10.1038\/srep11718","volume":"5","author":"JH Kang","year":"2015","unstructured":"Kang JH, Lin HC, Kao S, Tsai MC, Chung SD. Alopecia areata increases the risk of stroke: a 3-year follow-up study. Sci Rep. 2015;5:11718. https:\/\/doi.org\/10.1038\/srep11718.","journal-title":"Sci Rep"},{"key":"932_CR33","doi-asserted-by":"publisher","unstructured":"King B, Mostaghimi A, Shimomura Y, Piraccini BM, Blume-Peytavi U, Sontag A, et al. 51436 Safety analysis of baricitinib in adult patients with severe alopecia areata from 2 randomized clinical trials over a median of 2.3 years and up to 4 years of exposure. J Am Acad Dermatol. 2024;91(3):AB82. https:\/\/doi.org\/10.1016\/j.jaad.2024.07.336.","DOI":"10.1016\/j.jaad.2024.07.336"},{"issue":"1","key":"932_CR34","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1038\/s41598-018-28142-1","volume":"8","author":"JH Lee","year":"2018","unstructured":"Lee JH, Song Y, Do Han K, Park YM, Lee JY, Park YG, et al. Cancer risk by the subtype of alopecia. Sci Rep. 2018;8(1):9748. https:\/\/doi.org\/10.1038\/s41598-018-28142-1.","journal-title":"Sci Rep"},{"issue":"7","key":"932_CR35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/jamadermatol.2020.1133","volume":"156","author":"JW Shin","year":"2020","unstructured":"Shin JW, Kang T, Lee JS, Kang MJ, Huh CH, Kim MS, et al. Time-dependent risk of acute myocardial infarction in patients with alopecia areata in Korea. JAMA Dermatol. 2020;156(7):763\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1133.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"932_CR36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/01.atv.17.2.375","volume":"17","author":"CE Walden","year":"1997","unstructured":"Walden CE, Retzlaff BM, Buck BL, McCann BS, Knopp RH. Lipoprotein lipid response to the National Cholesterol Education Program step II diet by hypercholesterolemic and combined hyperlipidemic women and men. Arterioscler Thromb Vasc Biol. 1997;17(2):375\u201382. https:\/\/doi.org\/10.1161\/01.atv.17.2.375.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00932-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:18:12Z","timestamp":1751617092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00932-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00932-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"10 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Eli Lilly and Company under license from Incyte Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Brett King has served on advisory boards and\/or is a consultant and\/or a clinical trial investigator and\/or is on a data monitoring committee for AbbVie, Almirall, AltruBio, AnaptysBio, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Bioniz Therapeutics, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly and Company, Equillium, Horizon Therapeutics, Incyte Corporation, Janssen, LEO Pharma, Merck, Otsuka\/Visterra, Pfizer, Q32 Bio, Regeneron, Sanofi Genzyme, Sun Pharma, Twi Biotechnology, Ventyx Biosciences, and Viela Bio; has served on speaker\u2019s bureaus for AbbVie, Eli Lilly and Company, Incyte Corporation, Pfizer, Regeneron, and Sanofi Genzyme; and is a scientific advisor for BiologicsMD. Arash Mostaghimi has been a consultant for AbbVie, Concert Pharmaceuticals, Digital Diagnostics, Eli Lilly and Company, and Pfizer. Yutaka Shimomura has been an investigator for Eli Lilly and Company. Bianca Maria Piraccini has received honoraria from or been a consultant for Almirall, Eli Lilly and Company, ISDIN, Pfizer, and Vichy Laboratoires. Ulrike Blume-Peytavi has served as a consultant for and\/or received grants and\/or honoraria from AbbVie, Boots Healthcare, Concert Pharmaceuticals, Eli Lilly and Company, NeuroDerm, Novartis, Pfizer, Sanofi Regeneron, and Vichy Laboratoires. Angelina Sontag, Yves Dutronc, Karen Denning, Jill Kolodsick, and Ayush Srivastava are employees and stockholders of Eli Lilly and Company. Xiaoyu Lu is an employee of TechData Service Company. Rodney Sinclair has been an investigator for and\/or provided professional services to AbbVie, Aerotek Scientific, Akeso Biopharma, Amgen, Arcutis, Arena Pharmaceuticals, Ascend Laboratories, AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus BioSciences, Connect Biopharma, Cutanea, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, LEO Pharma, MedImmune\/AstraZeneca, Merck Sharp & Dohme, Novartis, Oncobiologics, Pfizer, Regeneron, Reistone Biopharma, Roche, Samson Medical Technologies, Sanofi, Sun Pharma, and UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The BRAVE-AA1 and BRAVE-AA2 studies were conducted in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and the research protocols were approved by each center\u2019s institutional review board or ethics committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written informed consent for inclusion in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided written informed consent for the use of their de-identified anonymized aggregated data and their case details for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the USA and the European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data-sharing environment. For details on submitting a request, see the instructions provided at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors authorship criteria and have read and approved the final version. AS, YD, KD, JK, XL, and AS contributed to the study conception and design, data analysis and interpretation, and manuscript drafting and revision. BK, AM, YS, BMP, UB-P, and RS contributed to the data interpretation and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}